Analyst consensus rating

Halozyme Therapeutics Analyst Rating: Buy

Direct answer

Halozyme Therapeutics's consensus rating is Buy.

9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $119.89.
Forecast evidence checked November 15, 2026.

Get free Halozyme Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$100.27
Average price target
$119.89
High price target
$149.00
Low price target
$79.00
Low target gap
-21.2%
Target upside
+19.6%
High target gap
+48.6%
Target range width
69.8%
Consensus rating
Buy
Analysts
9
Evidence date
November 15, 2026
Valid through
November 22, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Halozyme Therapeutics?

Halozyme Therapeutics has a verified Buy consensus. The same dataset has an average price target of $119.89.

How far are Halozyme Therapeutics's low and high targets from the recorded price?

The low target implies -21.2%, while the high target implies +48.6%.

How many analysts are included in Halozyme Therapeutics's consensus?

The verified consensus includes 9 analysts.

How is Halozyme Therapeutics's target upside or downside calculated?

The average target of $119.89 is divided by the recorded price of $100.27, then one is subtracted to produce +19.6%. This does not guarantee a future return.

When was Halozyme Therapeutics's analyst forecast verified?

The data was verified on 2026-11-15. The dataset is valid through 2026-11-22.